EuroMedLab 2019
EuroMedLab 2019
Join us for EuroMedLab 2019!
Randox Laboratories will be attending EuroMedLab from the 19th – 23rd May 2019. Our innovative diagnostic solutions have been developed with consolidation and economy in mind, providing cost savings whilst using pioneering technology.
Diagnostics is our passion. We are dedicated to developing solutions that not only meet your needs, but that are of the highest quality, the most reliable and the most cost-effective. We look forward to meeting you in the Barcelona International Convention Centre, at our booth No. 184.
Register your attendance at one of our industry sponsored workshops
The industry specific workshops are open to all congress attendees on a first come, first-served basis.
Development and clinical evaluation of an automated multi-analyte biochip array for rapid stroke diagnosis | Room 116 | Mon, 20 May 2019 , 14:45 – 15:45
Secreted Phospholipases A2 and Cardiovascular Risk | Room 116 | Tue, 21 May 2019 , 12:30 – 13:30
Novel Multiplex Molecular Diagnostics: A Cross-Platform Comparison | Room 117 | Tue, 21 May 2019, 14:45 – 15:45
What can we offer?
Randox Biosciences is part of Randox Laboratories and is dedicated to advancing scientific discovery, drug development and diagnostics. We provide a variety of services and products to numerous industries including clinical laboratories, biopharma and academic research institutes.
Our revolutionary multiplex Biochip Array Technology includes multiplex protein immunoassays and multiplex nucleic acid arrays, and is delivered via the award winning Evidence range of analysers. Biochip Array Technology is a multi-analyte testing platform facilitating the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample. Biochip provides a unique platform for assessment in a rapid, accurate and easy to use format.
Vivalytic
Vivalytic the newest offering from Randox Biosciences brings innovation to the Molecular Diagnostic industry providing tests for respiratory, genitourinary and hospital acquired infections. The Vivalytic platform is capable of both Hi-Plex and Lo-Plex testing. Nucleic acid extraction, PCR amplification followed by a suite of detection methods are combined in a truly revolutionary, fully automated platform. Manual preparation, cold chain reagents and the use of multiple devices are no longer required making Vivalytic a unique space-saving, hygienic solution for Molecular Diagnostic testing.
Join our workshop on Tuesday 21st May 2019 to learn more about molecular testing and how 44 pathogens can be tested from a single patient sample.
Acusera
Leading provider of true third-party controls
With over 390 parameters available in our Acusera range, choice and flexibility is guaranteed. Moreover, the availability of truly independent third-party controls coupled with the added advantages of highly accurate target values, excellent stability and unparalleled quality will enhance performance, save valuable time and minimise waste in any laboratory. Our comprehensive range of multi-analyte controls have been uniquely developed with user convenience in mind. By combining more than 100 parameters in a single vial, laboratories can significantly reduce the need for multiple, costly single analyte controls.
Acusera 24.7
Online QC software with real-time peer group statistics
Designed to help you efficiently review QC data from multiple laboratory instruments on one centralised platform, Acusera 24.7 allows quick and easy identification of QC failures and emerging trends.
Unique access to live peer group updates will reduce time and money spent troubleshooting, helping you to instantly discover if an issue is isolated to your lab or a widespread problem. The added benefit of automatically generated statistics including Sigma Scores, Measurement Uncertainty & Total Error as well as fully interactive charts & reports will enable quick and easy performance monitoring.
Acusera Verify
Meet CLIA requirements with accuracy and ease
Acusera Linearity Sets are designed to challenge a larger section of an instruments reportable range and test if a system’s calibration is still valid. Our linearity materials cover a wide range of testing including, CRP, RF, Lipids, Therapeutic Drugs, Esoterics and more. Designed with user convenience in mind, all our linearity sets are supplied in a liquid format, while also presented in varying levels. Our unique combination of analytes enables laboratories to reduce the number of individual products required while ultimately reducing costs and time.
Complimentary, cloud-based data reduction software is supplied with all linearity sets, providing a graphical representation of results for at-a-glance performance assessment. Access to instantly updated peer group data and automatically generated statistics also helps to speed up data review.
The World’s Largest International EQA scheme
With over 45,000 laboratory participants in more than 133 countries, the Randox International Quality Assessment Scheme (RIQAS) is truly the largest international EQA provider in the world. Our comprehensive product offering currently covers over 360 parameters across 33 flexible programmes. Each RIQAS programme contains a unique combination of parameters meaning laboratories can significantly reduce the number of individual programs required while increasing efficiency and reducing costs. Further benefits to a laboratory include accreditation to ISO 17043:2010, frequent reporting, reduced parameter options and access to comprehensive yet user-friendly reports.
Molecular Infectious Disease Controls
Qnostics is a leading manufacturer of Third Party Quality Control solutions for Molecular Infectious Disease testing. Supplying microbiology/virology laboratories, molecular diagnostic assay manufacturers, EQA providers, pharmaceutical and CRO organisations for over a decade.
Designed to meet the demand of today’s molecular diagnostics laboratory and laboratories carrying out Nucleic Acid Testing (NAT), the Qnostics Molecular Infectious Disease range comprises hundreds of characterised viral, bacterial and fungal targets covering a wide range of Transplant Associated Diseases, Respiratory Infections, Blood Borne Viruses, Sexually Transmitted Infections, Gastrointestinal Diseases and Central Nervous System Diseases.
Join our workshop on Tuesday 21st May 2019 to learn more about molecular testing and how 44 pathogens can be tested from a single patient sample.
Molecular External Quality Control
QCMD is a world leading External Quality Assessment (EQA) / Proficiency Testing (PT) scheme, dedicated to improving the quality of molecular diagnostic assays used in the detection of infectious diseases. With an extensive database of over 2000 participants in over 100 countries, QCMD is one of the largest providers of molecular EQA in the field of infectious disease testing.
EQA participants receive an individual report outlining their performance relative to their method and technology groups. A supplementary report may be commissioned – this includes any additional relevant information regarding the annual EQA distribution, as well as scientific expert commentary and feedback on the overall results within that distribution.
Randox Reagents are internationally recognised as being of the highest quality, offering reliable and rapid results. Our product portfolio consists of 113 clinical chemistry assays, covering a range of testing panels, including: antioxidants, diabetes, drugs of abuse testing, cardiology and lipids, specific proteins, therapeutic drug monitoring and veterinary testing.
Randox are continuously striving to improve diagnostic solutions worldwide. As a result, Randox have produced 29 niche and superior performance assays, including: 5th Generation Bile Acids, Adiponectin, Aldolase, Copper, Cystatin C, D-3-Hydroxybutyrate, G6PDH, H-FABP, Lipoprotein (a), NEFA, HDL2/3 Cholesterol, sdLDL Cholesterol, Total Antioxidant Status and Zinc.
Enhance your Cardiac Testing Panel with sPLA2-IIA!
sPLA2-IIA is thought to be the most highly expressed enzyme from the secretory phospholipase A2 family. sPLA2-IIA is expressed in the normal arterial wall and its expression is readily up-regulated by inflammatory stimuli. It’s production of fatty acids and biologically active phospholipids plays an important role in platelet, monocyte, and endothelial activation, processes known to be critical steps in atherogenesis.
Join our workshop on Tuesday 21st May 2019 to learn more about sPLA2-IIA’s role in inflammatory conditions, including its prediction in cardiovascular risk.
Renowned for quality and reliability, the RX series leads the way with the world’s most extensive dedicated clinical chemistry test menu comprising routine chemistries, specific proteins, lipids, therapeutic drugs, drugs of abuse, antioxidants, veterinary and diabetes testing. Guaranteeing real cost savings through consolidation of routine and specialised tests onto a single platform, the RX series of analysers delivers excellence in patient care, offering unrivalled precision, accuracy and reliability.
RX misano
The RX misano semi-automated analyser has been developed with the user in mind by incorporating a responsive touch-screen display. The sleek ergonomic design boasts intuitive user-friendly software allowing for test menu personalisation and ease of use. The RX misano is capable of high standard, precise results at a competitive price per test.
RX monaco
The RX monaco is a fully automated solution for low to mid volume clinical chemistry testing offering the ultimate in convenience, performance and confidence. At optimal configuration, the RX monaco performs 170 tests per hour providing cost effective, high quality testing.
RX daytona +
The RX daytona+ is a fully automated, benchtop, clinical chemistry analyser capable of performing high quality testing, with a combined throughput of 450 tests per hour, for accurate results you can trust. The most versatile analyser in its class, the RX daytona+ combines robust hardware and intuitive software with the world leading RX series test menu for unrivalled performance with direct HbA1c testing capabilities.
RX imola
The RX imola is a cost-effective system that delivers consistent high-quality results. Capable of handling the workload of a medium to high throughout laboratory and a combined throughput of 560 tests per hour, the RX imola provides rapid, comprehensive testing on a small footprint analyser with direct HbA1c testing capabilities. The RX imola is a fully automated system with random access and STAT sampling functionality, boosting productivity and saving time when it matters most
RX modena
Capable of performing up to 1,200 tests per hour, with direct HbA1c testing capabilities, the RX modena consolidates all your assay requirements onto one intuitive platform. The RX modena boasts icon based, interactive touch-screen technology adding a modern flair to your laboratory.
Randox Toxicology offer the most comprehensive Drugs of Abuse (DoA) test menu across multiple forensic matrices. Our level of expertise in toxicology research and development allows us to adapt quickly to ever changing market influences and develop assays for current and novel drug trends. Excellent assay precision and performance eliminates false reporting, therefore reducing unnecessary confirmatory tests and time lost in the laboratory as a result. Our Biochip Arrays offer CVs typically less than 10%, producing an accurate drug profile to ensure confidence in results.
Evidence series immunoassay analysers guarantee cost-effective, highly accurate and flexible testing solutions. Having been developed to work with patented Biochip Array Technology, this precision multiplex testing platform allows for the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample.
This multiplex system delivers an unrivalled increase in patient information, offering a more in-depth diagnostic profile with each patient sample. This further analysis places the focus on the diagnosis, and on improving patient outcomes.
Want to know more?
Contact us or book a meeting with us
View our list of scientific posters that will be on display at EuroMedLab
Rapid simultaneous screening (less than 23 minutes) of twenty drug classes from a single whole blood sample on the biochip analyser Evidence MultiSTAT | Display time: 10.00am – 5.30pm | Presenter: P. Robinson (Randox Toxicology)
Evaluation of the effect of more frequent reporting in analytical performance through the use of an international external quality assessment scheme | Display time: 10.00am – 5.30pm | Presenter: L. Adams (Randox Laboratories Ltd.)
Development of a biochip array for the simultaneous detection of twelve cytokines on the new random access fully automated Evidence Evolution analyser | Display time: 10.00am – 5.30pm | Presenter: G. Donnellan (Randox Teoranta)
Analytical performance evaluation of an assay for the direct measurement of HbA1c in whole blood on RX series analysers of different throughput | Display time: 10.00am – 5.30pm | Presenter: E. Lenehan (Randox Laboratories Ltd)
Development of a new biochip based immunoassay for the determination of the bone formation biomarker N-terminal propeptide of type 1 collagen (P1NP) | Display time: 10.00am – 5.30pm | Presenter: H. Stott (R&D Randox Biosciences)
Development of a biochip-based immunoassay for the specific detection of the Wnt signalling antagonist DKK1 | Display time: 10.00am – 5.30pm | Presenter: H. Stott (R&D Randox Biosciences)
Development of a highly specific monoclonal antibody pair for the detection of sclerostin, a regulator of bone turnover | Display time: 10.00am – 5.30pm | A. Connolly (Randox Teoranta)
Biomarker glycosylation evaluation in pancreatic cancer utilizing biochip array technology | Display time: 10.00am – 5.30pm | A. Connolly (Randox Teoranta)
Randox pledges commitment to business in Europe
Global healthcare firm Randox Laboratories has pledged its commitment to maintaining and developing its business relationships with Europe, as a group of 20 representatives from the diagnostics company have travelled to Greece this week, to take part in one of Europe’s largest diagnostics conference in Athens.
EuroMedLab, which is run by the European Congress of Clinical Chemistry and Laboratory Medicine, is attended by thousands of healthcare professionals from across the globe, and offers Randox the opportunity to showcase their capabilities and to network with key decision makers.
Managing Director of Randox, Dr. Peter FitzGerald, commented on what the company hopes to achieve by attending EuroMedLab;
“We highly value the business we do within the European market and have successfully made a name for ourselves in the diagnostics industry in these countries. We already have a number of key sales offices and distribution centres in the likes of France, Germany, Portugal, Italy, Spain and Poland, but there is so much more we can do. Attending key networking events such as EuroMedLab is vital because it allows us the opportunity to meet with our existing customers and partners, to nurture and develop these relationships, and of course establish new ones.”
At the EuroMedLab conference the delegation team of Randox scientists, business development executives and market researchers will be making a series of announcements and presentations for new products including an innovative stroke diagnostic, newly discovered biomarkers for coronary heart disease risk, and the latest in laboratory quality assurance software.
The team will also present for the first time the Evidence Evolution analyser, a biochip testing platform capable of delivering accurate results from more than 2600 tests an hour including, but not exclusive to, cancer surveillance, fertility, heart, nutritional, digestive and diabetes health.
Dr. FitzGerald continued;
“At Randox we invest up to 16% of our turnover in R&D and we therefore have more new tests in development than any other diagnostics company in the world. This puts us in a very unique position in the market because our new developments, which are focused in areas where they are needed the most, successfully address the most urgent health issues.
“In light of recent political developments, there will of course be particular business challenges in Europe, but at Randox we will maintain our commitment to nurturing our relationships with key business partners in Europe and to seeking new opportunities in international markets such as the US.”
EuroMedLab runs from the 11th – 15th June 2017 at the Megaron Athens International Conference Centre in Athens. Randox can be found at booth #13 in the Skalkotas Hall Foyer.
For further information about EuroMedLab visit http://euromedlab.randox.com/ or contact Randox PR on 028 9445 1016 or email RandoxPR@randox.com
Randox showcasing NI innovation at Europe’s biggest medical expo
Global biotechnology firm Randox is unveiling its latest, state-of-the-art laboratory technology at one of the biggest medical exhibitions in the world.
Randox, headquartered in County Antrim, is exhibiting at EuroMedLab in Paris, where it is launching its new clinical healthcare analyser; the RX misano, which will be exported to hospitals, veterinary clinics and teaching laboratories across the globe.
The machine; the latest of a range of equipment designed and manufactured by Randox, is attracting the attention of key international customers, across the world.
Graeme McNeill, Global Sales Manager at Randox says the new analyser has been developed to offer cutting-edge technology and functionality, typically associated with larger instruments, on a small footprint analyser.
“At Randox we have utilised our talents and experience in the life sciences, software development and engineering to create this pioneering technology, building on over a decade of R&D for this particular product range.
“The new RX misano shines a new light on semi-automated chemistry testing with its touch screen technology and here in Paris, we have had interest from Ministries of Health, leading clinics and research institutes around the world.”
Dr Peter FitzGerald, MD at Randox, says the company is proud to be promoting Northern Ireland’s innovation to an international audience:
“Randox is committed to improving healthcare worldwide and our clinical chemistry analysers are already in place in 120 countries; but this new machine is the next generation in Randox diagnostic capabilities. It will ensure that clinicians get the most reliable and accurate results and more quickly – allowing patients to be treated effectively and efficiently.
“The RX misano is the epitome of our ambition, our innovation and is indicative of the high-calibre scientific, engineering and software talent we have in the region.”
Randox is also showcasing a new test which is a key predictor for cardio-vascular disease and heart attacks. The test identifies a biomarker in the blood called SPLA2; people with high levels of this biomarker can be three times more likely to suffer a severe coronary event.
EuroMedLab 2015, runs from the 22nd- 24th of June at the Palais de Congrés de Paris.
The RX misano is currently unavailable to purchase in Germany
